Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1971 Dec;43(4):747–756. doi: 10.1111/j.1476-5381.1971.tb07210.x

A new dopamine-β-hydroxylase inhibitor

Effects on the noradrenaline concentration and on the action of L-DOPA in the spinal cord

N -E Andén, K Fuxe
PMCID: PMC1665707  PMID: 4339882

Abstract

1. The dopamine-β-hydroxylase inhibitor bis(4-methyl-1-homopiperazinyl-thiocarbonyl) disulphide (FLA-63; 25 mg/kg i.p.) caused within 4 h a 65% loss of noradrenaline throughout the intact rat spinal cord and also cranial to a transection of the cut spinal cord. Caudal to the lesion, there was only an insignificant depletion of 17% indicating the importance of nerve impulses for the disappearance of noradrenaline.

2. Dopamine accumulated in the spinal cord after treatment with FLA-63 although the amounts were not sufficient to replace the missing noradrenaline. Even after treatment with L-3,4-dihydroxyphenylalanine (L-DOPA), the catecholamine store was incompletely replenished by dopamine.

3. After a large depletion of the noradrenaline stores, induced by repeated doses of FLA-63 or by reserpine plus FLA-63, the L-DOPA-induced increase in flexor reflex activity of the hind limbs of spinal rats was inhibited much more than after pretreatment with α-methyl-tyrosine or reserpine. FLA-63 blocked the formation of noradrenaline but not of dopamine from L-DOPA.

4. The increase in flexor reflex activity induced by the noradrenaline receptor stimulating agent clonidine was not changed by FLA-63, indicating that the noradrenaline receptor sensitivity was not influenced.

5. After depletion of the noradrenaline stores, the small formation of noradrenaline from L-DOPA may be of greater functional significance for the noradrenaline receptor stimulation than the greater formation of dopamine, but the dopamine formed also has a slight action. With intact noradrenaline stores, displacement of endogenous noradrenaline by newly formed dopamine contributes, at least after monoamine oxidase inhibition, to the increase in the flexor reflex activity caused by L-DOPA.

Full text

PDF
747

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDEN N. E., HAEGGENDAL J., MAGNUSSON T., ROSENGREN E. THE TIME COURSE OF THE DISAPPEARANCE OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE SPINAL CORD AFTER TRANSECTION. Acta Physiol Scand. 1964 Sep-Oct;62:115–118. doi: 10.1111/j.1748-1716.1964.tb03958.x. [DOI] [PubMed] [Google Scholar]
  2. Andén N. E., Carlsson A., Häggendal J. Adrenergic mechanisms. Annu Rev Pharmacol. 1969;9:119–134. doi: 10.1146/annurev.pa.09.040169.001003. [DOI] [PubMed] [Google Scholar]
  3. Andén N. E., Corrodi H., Fuxe K., Hökfelt B., Hökfelt T., Rydin C., Svensson T. Evidence for a central noradrenaline receptor stimulation by clonidine. Life Sci. 1970 May 1;9(9):513–523. doi: 10.1016/0024-3205(70)90207-9. [DOI] [PubMed] [Google Scholar]
  4. Andén N. E., Corrodi H., Fuxe K., Hökfelt T. Increased impulse flow in bulbospinal noradrenaline neurons produced by catecholamine receptor blocking agents. Eur J Pharmacol. 1967 Oct;2(1):59–64. doi: 10.1016/0014-2999(67)90024-6. [DOI] [PubMed] [Google Scholar]
  5. Andén N. E., Fuxe F., Hökfelt T. The importance of the nervous impulse flow for the depletion of the monoamines from central neurones by some drugs. J Pharm Pharmacol. 1966 Sep;18(9):630–632. doi: 10.1111/j.2042-7158.1966.tb07949.x. [DOI] [PubMed] [Google Scholar]
  6. Andén N. E., Fuxe K., Henning M. Mechanisms of noradrenaline and 5-hydroxytryptamine disappearance induced by alpha-methyl-dopa and alpha-methyl-metatyrosine. Eur J Pharmacol. 1969 Dec;8(3):302–309. doi: 10.1016/0014-2999(69)90039-9. [DOI] [PubMed] [Google Scholar]
  7. Andén N. E., Fuxe K., Hökfelt T. Effect of some drugs on central monoamine nerve terminals lacking nerve impulse flow. Eur J Pharmacol. 1967 May;1(3):226–232. doi: 10.1016/0014-2999(67)90008-8. [DOI] [PubMed] [Google Scholar]
  8. Andén N. E., Jukes M. G., Lundberg A. The effect of DOPA on the spinal cord. 2. A pharmacological analysis. Acta Physiol Scand. 1966 Jul-Aug;67(3):387–397. doi: 10.1111/j.1748-1716.1966.tb03325.x. [DOI] [PubMed] [Google Scholar]
  9. BERTLER A., CARLSSON A., ROSENGREN E. A method for the fluorimetric determination of adrenaline and noradrenaline in tissues. Acta Physiol Scand. 1958 Dec 15;44(3-4):273–292. doi: 10.1111/j.1748-1716.1958.tb01627.x. [DOI] [PubMed] [Google Scholar]
  10. CARLSSON A., FALCK B., FUXE K., HILLARP N. A. CELLULAR LOCALIZATION OF MONOAMINES IN THE SPINAL CORD. Acta Physiol Scand. 1964 Jan-Feb;60:112–119. doi: 10.1111/j.1748-1716.1964.tb02874.x. [DOI] [PubMed] [Google Scholar]
  11. CARLSSON A., LINDQVIST M. In-vivo decarboxylation of alpha-methyl DOPA and alpha-methyl metatyrosine. Acta Physiol Scand. 1962 Jan;54:87–94. doi: 10.1111/j.1748-1716.1962.tb02331.x. [DOI] [PubMed] [Google Scholar]
  12. CARLSSON A., MAGNUSSON T., ROSENGREN E. 5-HYDROXYTRYPTAMINE OF THE SPINAL CORD NORMALLY AND AFTER TRANSECTION. Experientia. 1963 Jul 15;19:359–359. doi: 10.1007/BF02152316. [DOI] [PubMed] [Google Scholar]
  13. CARLSSON A., WALDECK B. A fluorimetric method for the determination of dopamine (3-hydroxytyramine). Acta Physiol Scand. 1958 Dec 15;44(3-4):293–298. doi: 10.1111/j.1748-1716.1958.tb01628.x. [DOI] [PubMed] [Google Scholar]
  14. Carlsson A., Fuxe K., Hökfelt T. Failure of dopamine to accumulate in central noradrenaline neurons after depletion with diethyldithiocarbamate. J Pharm Pharmacol. 1967 Jul;19(7):481–483. doi: 10.1111/j.2042-7158.1967.tb08116.x. [DOI] [PubMed] [Google Scholar]
  15. Carlsson A., Lindqvist M., Fuxe K., Hökfelt T. Histochemical amd biochemical effects of diethyldithiocarbamate on tissue catecholamines. J Pharm Pharmacol. 1966 Jan;18(1):60–62. doi: 10.1111/j.2042-7158.1966.tb07773.x. [DOI] [PubMed] [Google Scholar]
  16. Corrodi H., Fuxe K., Hamberger B., Ljungdahl A. Studies on central and peripheral noradrenaline neurons using a new dopamine-(beta)-hydroxylase inhibitor. Eur J Pharmacol. 1970 Oct;12(2):145–155. doi: 10.1016/0014-2999(70)90059-2. [DOI] [PubMed] [Google Scholar]
  17. Corrodi H., Fuxe K., Hökfelt T. Refillment of the catecholamine stores with 3,4-dihydroxyphenylalanine after depletion induced by inhibition of tyrosine-hydroxylase. Life Sci. 1966 Apr;5(7):605–611. doi: 10.1016/0024-3205(66)90291-8. [DOI] [PubMed] [Google Scholar]
  18. Corrodi H., Hanson L. C. Central effects of an inhibitor of tyrosine hydroxylation. Psychopharmacologia. 1966;10(2):116–125. doi: 10.1007/BF00455973. [DOI] [PubMed] [Google Scholar]
  19. Florvall L., Corrodi H. Dopamine beta-hydroxylase inhibitors. The preparation and the dopamine beta-hydroxylase inhibitory activity of some compounds related to dithiocarbamic acid and thiuramdisulfide. Acta Pharm Suec. 1970 Feb;7(1):7–22. [PubMed] [Google Scholar]
  20. Goldstein M. Inhibition of norepinephrine biosynthesis at the dopamine-beta-hydroxylation stage. Pharmacol Rev. 1966 Mar;18(1):77–82. [PubMed] [Google Scholar]
  21. Goldstein M., Nakajima K. The effect of disulfiram on catecholamine levels in the brain. J Pharmacol Exp Ther. 1967 Jul;157(1):96–102. [PubMed] [Google Scholar]
  22. HAEGGENDAL J. AN IMPROVED METHOD FOR FLUORIMETRIC DETERMINATION OF SMALL AMOUNTS OF ADRENALINE AND NORADRENALINE IN PLASMA AND TISSUES. Acta Physiol Scand. 1963 Nov;59:242–254. doi: 10.1111/j.1748-1716.1963.tb02739.x. [DOI] [PubMed] [Google Scholar]
  23. HARRISON W. H., LEVITT M., UDENFRIEND S. NOREPINEPHRINE SYNTHESIS AND RELEASE IN VIVO MEDIATED BY 3,4-DIHYDROXYPHENETHYLAMINE. J Pharmacol Exp Ther. 1963 Nov;142:157–162. [PubMed] [Google Scholar]
  24. MUSACCHIO J. M., KOPIN I. J., WEISE V. K. SUBCELLULAR DISTRIBUTION OF SOME SYMPATHOMIMETIC AMINES AND THEIR BETA-HYDROXYLATED DERIVATIVES IN THE RAT HEART. J Pharmacol Exp Ther. 1965 Apr;148:22–28. [PubMed] [Google Scholar]
  25. Musacchio J. M., Fischer J. E., Kopin I. J. Subcellular distribution and release by sympathetic nerve stimulation of dopamine and alpha-methyl dopamine. J Pharmacol Exp Ther. 1966 Apr;152(1):51–55. [PubMed] [Google Scholar]
  26. Musacchio J. M., Goldstein M., Anagnoste B., Poch G., Kopin I. J. Inhibition of dopamine-beta-hydroxylase by disulfiram in vivo. J Pharmacol Exp Ther. 1966 Apr;152(1):56–61. [PubMed] [Google Scholar]
  27. Persson T., Waldeck B. Further studies on the possible interaction between dopamine and noradrenaline containing neurons in the brain. Eur J Pharmacol. 1970;11(3):315–320. doi: 10.1016/0014-2999(70)90007-5. [DOI] [PubMed] [Google Scholar]
  28. Persson T., Waldeck B. Is there an interaction between dopamine and noradrenaline containing neurons in the brain? Acta Physiol Scand. 1970 Jan;78(1):142–144. doi: 10.1111/j.1748-1716.1970.tb04649.x. [DOI] [PubMed] [Google Scholar]
  29. Svensson T. H., Waldeck B. On the significance of central noradrenaline for motor activity: experiments with a new dopamine beta-hydroxylase inhibitor. Eur J Pharmacol. 1969 Sep;7(3):278–282. doi: 10.1016/0014-2999(69)90092-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES